

Online Resource 1

Symptom Severity and Exacerbation Frequency in Medically Treated Patients With Acromegaly

Pituitary

Eliza B. Geer, MD; David R. Clemmons, MD; Jill Sisco; Maxwell Koobatian, PhD; Janetrick C. Okeyo, PhD; Tiffany P. Quock, PhD, MS; Yang Wang, PhD; Raffaella Colzani, MD; Alan Krasner, MD

Corresponding author:

Alan Krasner, MD

Crinetics Pharmaceuticals, Inc.

akrasner@crinetics.com

Supplementary Table 1 Patient demographic and clinical characteristics

	Patients (<i>n</i> = 31)
Age, years, mean (SD)	53.4 (13.6)
Sex, <i>n</i> (%)	
Female	24 (77.4)
Male	6 (19.4)
Prefer not to say	1 (3.2)
Race/ethnicity, <i>n</i> (%)	
White	26 (83.9)
Hispanic or Latino	2 (6.5)
Asian American	1 (3.2)
Other	1 (3.2)
Prefer not to say	1 (3.2)
Geographic region, <i>n</i> (%)	
United States	22 (71.0)
Canada	6 (19.4)
United Kingdom	3 (9.7)
Comorbid conditions (self-reported), <i>n</i> (%)	
Arthritis	14 (45.2)
Diabetes	12 (38.7)

Sleep apnea	3 (9.7)
Carpal tunnel syndrome	1 (3.2)
Heart failure	1 (3.2)
Previous pituitary surgery, n (%)	31 (100)
Medical treatment	
Depot SRL monotherapy	15 (48.4)
Depot SRL + non-SRL monotherapy	16 (51.6)
>3 injections during the 3-month survey period, n (%)*	15 (48.4)

*Depot SRLs not approved for administration more frequently than monthly
SRL, somatostatin receptor ligand

